Tricida, Inc. (TCDA) |
| 0.108 0 (0%) 01-23 16:00 |
| Open: | 0.1156 |
| High: | 0.116 |
| Low: | 0.0925 |
| Volume: | 31,125,310 |
| Market Cap: | 6(M) |
| PE Ratio: | -0.02 |
| Exchange: | NASDAQ Global Select |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 0.03 |
| Resistance 1: | 0.03 |
| Pivot price: | 0.01 |
| Support 1: | 0.01 |
| Support 2: | 0.01 |
| 52w High: | 13.85 |
| 52w Low: | 0.0411 |
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
Financials
| EPS | -5.293 |
| Book Value | 2.170 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -60.1 |
| Return on Equity (ttm) | 0.0 |
Company news
Tue, 01 Jul 2025
Tricida Inc. $14.25M Stockholder Securities Settlement - Claim Depot
Thu, 03 Nov 2022
Peninsula kidney drug company weighs 'strategic alternatives' after clinical trial flop - The Business Journals
Mon, 24 Oct 2022
Why Is Tricida (TCDA) Stock Down 90% Today? - InvestorPlace
Mon, 24 Oct 2022
Tricida Shares Plunge 94% After Kidney Disease Drug Fails Trial - Barron's
Wed, 09 Feb 2022
Toragen, Inc. Announces Appointment of Dr. Sandra Coufal, M.D. as CEO - BioSpace
Wed, 05 Jan 2022
Chen Lin's Top 6 Investment Ideas - streetwisereports.com
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
